[go: up one dir, main page]

WO2015001568A3 - Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof - Google Patents

Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof Download PDF

Info

Publication number
WO2015001568A3
WO2015001568A3 PCT/IN2014/000438 IN2014000438W WO2015001568A3 WO 2015001568 A3 WO2015001568 A3 WO 2015001568A3 IN 2014000438 W IN2014000438 W IN 2014000438W WO 2015001568 A3 WO2015001568 A3 WO 2015001568A3
Authority
WO
WIPO (PCT)
Prior art keywords
sitagliptin
preparation
pharmaceutical composition
lipoate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000438
Other languages
French (fr)
Other versions
WO2015001568A2 (en
Inventor
Venkata Sunil Kumar Indukuri
Krishna Sumanth Peraka
Seeta Ram Anjaneyulu GORANTLA
Satyanarayana Chava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laurus Labs Pvt Ltd
Original Assignee
Laurus Labs Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Pvt Ltd filed Critical Laurus Labs Pvt Ltd
Publication of WO2015001568A2 publication Critical patent/WO2015001568A2/en
Publication of WO2015001568A3 publication Critical patent/WO2015001568A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to Sitagliptin lipoate salt and its polymorphic forms, a process for its preparation. The present invention also relates to a pharmaceutical composition using the Sitagliptin lipoate and its polymorphic forms.
PCT/IN2014/000438 2013-07-01 2014-07-01 Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof Ceased WO2015001568A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2913/CHE/2013 2013-07-01
IN2913CH2013 2013-07-01

Publications (2)

Publication Number Publication Date
WO2015001568A2 WO2015001568A2 (en) 2015-01-08
WO2015001568A3 true WO2015001568A3 (en) 2015-06-11

Family

ID=52144244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000438 Ceased WO2015001568A2 (en) 2013-07-01 2014-07-01 Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof

Country Status (1)

Country Link
WO (1) WO2015001568A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087054A1 (en) * 2017-11-01 2019-05-09 Zenvision Pharma Llp Novel pharmaceutical composition comprising dpp-4 inhibitor, alpha-lipoic acid and vitamin b12
CN116082346A (en) * 2023-04-12 2023-05-09 宙晟智维生命科学(上海)有限公司 High-fluidity sitagliptin phosphate monohydrate crystal and preparation method thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948810A (en) * 1993-12-21 1999-09-07 Asta Medica Aktiengesellschaft Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
US20030100563A1 (en) * 2001-07-06 2003-05-29 Edmondson Scott D. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20050032804A1 (en) * 2003-06-24 2005-02-10 Cypes Stephen Howard Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
WO2005020920A2 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005072530A1 (en) * 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
WO2006033848A1 (en) * 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2007035198A2 (en) * 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2008112166A2 (en) * 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2009085990A2 (en) * 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2009085223A1 (en) * 2007-12-20 2009-07-09 Indigene Pharmaceuticals, Inc. Combination of metformin r-(+)-lipoate and antihyperglycemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2010000469A2 (en) * 2008-07-03 2010-01-07 Ratiopharm Gmbh Crystalline salts of sitagliptin
WO2010056726A1 (en) * 2008-11-11 2010-05-20 Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetes
WO2013013833A1 (en) * 2011-07-27 2013-01-31 Farma Grs, D.O.O. Process for the preparation of sitagliptin and its pharmaceutically acceptable salts
WO2013084210A1 (en) * 2011-12-08 2013-06-13 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948810A (en) * 1993-12-21 1999-09-07 Asta Medica Aktiengesellschaft Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
US20030100563A1 (en) * 2001-07-06 2003-05-29 Edmondson Scott D. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20050032804A1 (en) * 2003-06-24 2005-02-10 Cypes Stephen Howard Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
WO2005020920A2 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005072530A1 (en) * 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
WO2006033848A1 (en) * 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2007035198A2 (en) * 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2008112166A2 (en) * 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2009085990A2 (en) * 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2009085223A1 (en) * 2007-12-20 2009-07-09 Indigene Pharmaceuticals, Inc. Combination of metformin r-(+)-lipoate and antihyperglycemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2010000469A2 (en) * 2008-07-03 2010-01-07 Ratiopharm Gmbh Crystalline salts of sitagliptin
WO2010056726A1 (en) * 2008-11-11 2010-05-20 Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetes
WO2013013833A1 (en) * 2011-07-27 2013-01-31 Farma Grs, D.O.O. Process for the preparation of sitagliptin and its pharmaceutically acceptable salts
WO2013084210A1 (en) * 2011-12-08 2013-06-13 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LESTER PACKER ET AL.: "Alpha-lipoic acid as a biological antioxidant", FREE RADICALS IN BIOLOGY & MEDICINE, vol. 19, no. ISSUE, August 1995 (1995-08-01), pages 227 - 250 *

Also Published As

Publication number Publication date
WO2015001568A2 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
EP3060541A4 (en) Methods and compounds for producing nylon 6,6
ZA201507571B (en) Process for making 2,5-furandicarboxylic acid
WO2016071435A3 (en) Synthesis of copanlisib and its dihydrochloride salt
IL241038A0 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
WO2015051868A8 (en) Pigments based on bismuth compounds
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
IL242437B (en) 5,9-dimethyl-9-hydroxy-decen-4-al compound, its use and process for its preparation
WO2016009401A3 (en) Preparation of tedizolid phosphate
MX2016001138A (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof.
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
IL233055A (en) (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene derivatives
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
HK1215571A1 (en) Cobicostat dichlohydrate salt
WO2017064558A8 (en) Novel immunostimulant
WO2015001568A3 (en) Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2014115169A3 (en) Crizotinib solid dispersion
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
EP2997009A4 (en) Process for the preparation of arformoterol or salt thereof
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
WO2017046816A3 (en) Process for the preparation of derivatives of benzodioxole
EP3121188A4 (en) Crystalline 3',5'-cyclic diguanylic acid
WO2015170340A3 (en) Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14819788

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14819788

Country of ref document: EP

Kind code of ref document: A2